Methods and device for treating opioid addiction
AssigneeTitan Pharmaceuticals, Inc.
InventorRajesh Patel
Life of this patent
Estimating the term…
Abstract
The invention described herein solves the challenges encountered in providing a safe, efficacious, and satisfactory option for the treatment of opioid addiction. Methods and devices of the invention allow a subject to receive an implantable formulation comprising an opioid receptor ligand, buprenorphine, or a metabolite thereof as a treatment for opioid addiction. The invention preempts several difficulties encountered with conventional methods for the treatment of opioid addiction, and by doing so the invention improves treatment adherence, compliance, subject satisfaction, and overall success rate.
Claims62
A method of treating opioid addiction in a subject in need thereof, the method comprising:
- implanting into the subject a device comprising a particulate of at least one opioid receptor ligand, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier, wherein the particulate has a mean particle size of about 5 μM to about 350 μM, and wherein the device releases a therapeutically-effective amount of the opioid receptor ligand or the pharmaceutically-acceptable salt thereof.
A method of treating opioid addiction in a subject in need thereof, the method comprising implanting into the subject a device comprising an opioid receptor ligand or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier, wherein the device has a tensile strength in a range of about 10,000 g/cm2 to about 110,000 g/cm2;
- and wherein the device releases a therapeutically-effective amount of the opioid receptor ligand, or the pharmaceutically-acceptable salt thereof.
A device comprising:
- at least one opioid receptor ligand, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier, wherein the device has a tensile strength in a range of about 10,000 g/cm2 to about 110,000 g/cm2;
- and wherein, upon implantation of the device in a subject, the device releases a therapeutically-effective amount of the opioid receptor ligand, or the pharmaceutically-acceptable salt thereof to the subject.
A device comprising:
- a particulate of at least one opioid receptor ligand, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier, wherein the particulate has a mean particle size of about 5 μM to about 350 μM, and wherein upon implantation of the device into a subject the device releases a therapeutically-effective amount of the opioid receptor ligand or the pharmaceutically-acceptable salt thereof to the subject.
Dependencies are inferred from the claim text.